All News

Both investigational vaccines induced strong immunity across all antigens and researchers reported no new safety signals, supporting phase 3 development.

RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.

Vaccination rates among US adults are roughly half that of pediatric populations, exposing older adults to risk for disease and complications, according to a new analysis.

RAD 2025: Chovatiya spoke at RAD about the need to better understand how treatments for AD are being used in the real world, after symptoms subside and skin signs clear.

RAD 2025: Jiade Yu, MD, discussed chronic hand eczema as a distinct condition from AD, highlighting its clinical burden and emerging treatments, such as delgocitinib.

Arcutis Biotherapeutics announced today the enrollment of the first patient in the phase 2 INTEGUMENT-INFANT trial.

The novel triple fixed-dose combination of telmisartan, amlodipine and indapamide, is the first of its kind approved for initial treatment of hypertension.

From primary care management of heavy menstrual bleeding to postpartum depression screening, find out what you may have missed at ACOG 2025.

The preventive monoclonal antibody is designed to protect infants against RSV infection through 5 months and is administered at the same dose, regardless of weight.

RAD 2025: As expert dermatologist Shahriari explains it, eczema may be just another rash on your schedule but for a patient, it could be the reason they don't leave the house.